340B Showdown: HHS Facing Mounting Congressional Pressure To Halt Pharma Challenges
Executive Summary
Bipartisan congressional letters seek relief from HHS but the Trump Administration has taken aim at 340B providers itself and may not be inclined to help.
You may also be interested in...
Pharma Pressure On 340B Contract Pharmacies Builds; How Will Biden’s HHS Respond?
President-elect Biden’s Administration may be less convinced than Trump’s about the need to make changes in the way providers benefit from the outpatient drug discount program.
Lilly’s 340B Restrictions: Jury Is Still Out On Appropriateness, But Optics Are Bad, HHS Says
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Pharma Manufacturers Mobilize Against 340B Discounts At Contract Pharmacies
AstraZeneca, Merck & Co., Sanofi and Novartis join Eli Lilly in taking action. But providers in the US federal discount program are pushing back.